FEATURED ARTICLES

• Expanding Into New Fields Of “Cell-Grow-Culture” For mRNA Transfection

  Learn about one path forward to navigate the pitfalls with mRNA transfection and a medium to assist in lentivirus-mediated transduction of human mesenchymal stromal/stem cells (hMSCs).

• Enhancing Lentiviral And AAV Transduction Of T Cells

  Learn about new data that highlights exciting uses for future immunotherapy studies.

• When The hMSC Meets The AAV

  Learn more about plausible benefits of AAV’s use in concert with hMSCs, and how a complete genetic engineering medium was expanded beyond lentivirus.

• Accelerate MSC And Exosome Therapies Into The Clinic

  Learn how to incorporate standardized cell banks & right-scaled processes into your experimental design for rapid implementation & robust, reproducible results.

• The Story Behind The Media

  Learn more about a system that fuels the rapid commercialization of scalable regenerative cures.

• Time To Scratch The “30-Year Itch” From MSCs’ Questions

  Explore some of the questions and theories behind why, after compelling pre-clinical and human safety data, MSC therapeutics are not progressing faster.

• Optimization Of Transient Transfection Of MSCs With Plasmid DNA Or mRNA

  Read through the results of our efforts to produce an optimal protocol for the transient transfection of hMSCs with pDNA or mRNA using non-viral means.

• Scale-Up Of A Xeno-Free Fed-Batch Stirred-Tank Bioreactor Process For hMSC Manufacturing

  See the results of our study to scale-up of a Xeno-Free (XF) fed batch microcarrier-based process for hMSC expansion in stirred tank reactors to the 50L scale.

• FBS-Based Media — Is It Time to Transition Between Traditions?

  We look into the signs that regenerative medicine can less afford FBS as high-quality sources become scarcer and how “cultivators” of hMSCs and other cells transition to a new, future-facing tradition.

• Development Of An Optimized Lentiviral Transduction Medium

  This work establishes an optimized genetic modification unit operation within the context of a scalable xeno-free manufacturing process to reproducibly generate populations of genetically modified hMSCs.

• The Role hMSCs Play In Bioengineering Solutions For Military Medicine

  Industry experts discuss developing functionally enhanced hMSCs as living bioreactors to serve as the next generation in bio-responsive drug delivery.

• When Considering Adipose Mesenchymal Stromal/Stem Cells

  Regardless of your favorite nomenclature for adipose tissue-derived hMSCs (hAD-MSCs, MSC(AT),AT-MSCs), there really is more beneath their story than meets the eye.

• Developing A Microcarrier Stirred Tank Process For Large-Scale hMSC-EV Production

  Discover how we successfully developed and optimized a process to maximize hMSC yield using microcarriers in a stirred tank bioreactor system.

• Considering Adipose Mesenchymal Stromal/Stem Cells

  Learn why allogeneic MSCs could be a favorable option in comparison with autologous MSCs.

• 3D Manufacturing Of Therapeutic hMSCs

  Discover how our microcarrier-based technology harvests hMSCs while showing high proliferation capacity, expression of hMSC-specific markers, significant trilineage differentiation potential, and strong immunomodulatory and angiogenic potency. 

• Extracellular Vesicle/Exosome Upstream Process Development: Maximizing Productivity To Accelerate Clinical Adoption

  In this blog, discover feasible strategies to maximize the number of hMSC-EVs generated by the upstream process and how to make well-engineered hMSC-EVs a thriving therapeutic modality.

• Maintaining CQAs As Manufacturing Processes Are Scaled From 2D To 3D Bioreactor Culture

  We discuss critical process parameters that may be utilized to control for CQAs in 3D bioreactor systems and the comparability of CQAs and functional attributes between hMSCs manufactured in 2D planar culture vs. 3D bioreactor culture.

• MSCs “Versus” Or MSCs “Via” T Cells For Cell & Gene Therapy?

  We explore how T cells and MSCs don’t have to compete for program time and resources—but can instead work together quite nicely!

• Manufacturing Platform & Media Strategy Matters For Mesenchymal Stromal/Stem Cell Production Economics

  Biopharmaceuticals need to scale up from laboratory to commercial production at a key point in their development and thus need clearly defined process economics to achieve critical velocity toward commercial success.

• Know Your Cost of Goods for Your Therapeutic Product & Process Development

  We discuss the importance of building a strong cost model with a step-by-step MSC-based example and illustrate how your model can positively impact your product and process development.